Showing 1196 results
- Media Release /Multiple Sclerosis Journal has published data from the ALITHIOS open-label extension study which provide a robust picture of the continuous safety data for Kesimpta, showing it was well tolerated in…
- Key Release /Annonce événementielle selon l’art. 53 RC Chiffre d’affaires du T1 en hausse de +5% (tcc1, +1% USD) et résultat opérationnel core en progression de 9% (tcc, +3% USD) Innovative Medicines (IM):…
- Key Release /Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im ersten Quartal um +5% (kWk1, +1% USD), das operative Kernergebnis wuchs um +9% (kWk, +3% USD) Innovative Medicines (IM) steigerte…
- Media Release /Diabetic macular edema (DME) is a leading cause of blindness in adults in developed countries; unmet needs in DME include improving fluid resolution in the retina and addressing the burden of…
- Key Release /Ad hoc announcement pursuant to Art. 53 LRNew simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of…
- Key Release /Ad-hoc-Mitteilung gemäss Art. 53 KRDie neue, vereinfachte Struktur und Organisation werden die Strategie von Novartis als fokussiertes Arzneimittelunternehmen unterstützen und die nächste Phase…
- Media Release /Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrated the efficacy and safety of continuous Kesimpta® (ofatumumab) treatment and in those switched from teriflunomide, with…
- Media Release /Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration (…
- Media Release /Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is…
- Media Release /Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4Cost savings from Lenalidomide Sandoz can expand treatment options for…
Pagination
- ‹ Previous page
- 1
- …
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- …
- 120
- › Next page